U.S. senators called for Medicare to offer broad coverage of Alzheimer’s treatments approved by the Food and Drug Administration, warning that current restrictions cost patients precious time as their disease progresses. They are asking the FDA to approve a drug based on hope, not science.
Alzheimers drugs
A new drug has been found to reduce memory decline among patients with early-stage Alzheimer’s in a “historic breakthrough” in treating the disease. Results have been reported by Eisai, a Tokyo-based pharmaceutical company that has partnered with U.S. biotech firm Biogen to develop lecanemab. The question is will HCPs trust Biogen?